M.B. Atkins

An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 Immunotherapy

Mark S. Klempner, Richard Noring, James W. Mier et al. · New England Journal of Medicine · 1990 · 145 citations · Full text

High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma

Jeffrey S. Abrams, Anthony A. Rayner, P H Wiernik et al. · JNCI Journal of the National Cancer Institute · 1990 · 71 citations

Renal Pathology, Immunology, Renal Inflammation +18

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

Toni K. Choueiri, Konstantin Penkov, Hiroji Uemura et al. · Annals of Oncology · 2024 · 37 citations · Full text

Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.

Herbert Tilg, Leland Shapiro, M.B. Atkins et al. · The Journal of Immunology · 1993 · 31 citations

Immunodeficiencies, Immunology, Immune Regulation +19

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

M.B. Atkins, Elizabeth R. Plimack, Igor Puzanov et al. · Annals of Oncology · 2016 · 31 citations · Full text

Urology, Genitourinary Cancer, Medicine +7